Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 16/20 | 0.46 |
| ▸ | RARA | P10276 | 14/20 | 0.46 |
| ▸ | RARG | P13631 | 14/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900887 | 0.94 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL13938671 | 0.94 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL3898558 | 0.94 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL3898555 | 0.94 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL3900892 | 0.94 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL14047270 | 0.84 | RARB (0.53) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL14029036 | 0.84 | MAPT (0.36) | RARBRARARARGMAPT | |
| SCHEMBL14029039 | 0.84 | MAPT (0.36) | RARBRARARARGMAPT | |
| SCHEMBL3894316 | 0.82 | RARB (0.49) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL3894321 | 0.82 | RARB (0.49) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194517-A1 | Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists | Io Therapeutics, Inc. (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194517-A1 | Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists | RARG, RARB, RARA | RARB 2/4885RARA 3/4885RARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.